MANALAPAN, NJ, Nov. 07, 2017 (GLOBE NEWSWIRE) -- RxS LLC (“RxS”), a privately held company providing multi-channel sample management solutions to pharmaceutical and biotech companies, today announced the introduction of its proprietary “Compliance Report Card” as part of the continued expansion of the company’s LinkedRx Suite of Reports and Dashboards. This new report simplifies the end-user experience in finding key data and information regarding a pharmaceutical sales representative’s PDMA based transactions through a consolidated trending report. Information contained in this single report includes all compliance related transactions, sample management help desk correspondences, and trending views of the representative’s reconciliations, audits and other key metrics.
The key advantage to RxS’s Compliance Report Card is that clients will have ready access to the consolidated view of a Sales Representative sample management activity. Prior to this breakthrough, it may have required deciphering as many as 10 different reports to get the holistic view of the representative information clients now can review in one consolidated report to initiate needed analysis.
This announcement comes on the heels of RxS’s recent participation at the 2017 PDMA Alliance Sharing Conference where RxS co-founder and principal, Mark Jara, was a featured presenter. He was also elected by his peers to a three-year term on the PDMA Alliance board. As a company, RxS has actively participated and supported this PDMA Alliance event since the company’s inception in 2011. The company was a Signature Sponsor of the conference in 2017.
“We had a great and valuable experience at the 2017 Sharing Conference,” says Jara. “We were excited to have the opportunity to share how our service model and technology are key to overcoming the administrative aspects of multi-channel sample management compliance, yet were equally pleased to hear direct feedback about our upcoming Compliance Report Card release.”
Rollout of the Compliance Report Card has already begun with existing RxS clients, with a full launch anticipated to take place through the fourth quarter of 2017 and into 2018. While this toolset expansion adds the consolidated report, the enhanced capabilities will come at no additional expense for existing clients.
As a service organization enabled by technology, RxS offers clients best-in-class multi-channel sample management and compliance along with other competitive advantages. For example, RxS helps clients harness data analytics for essential marketing efforts. RxS provides these services to all clients, small and large. Their innovative solutions and customer-centric focus have resulted in a recent surge in new clients. This growth has allowed the company to recently move to a larger, more client-friendly location in Manalapan, New Jersey. To learn more about RxS offerings, please visit rxsinfo.com.
RxS LLC, a privately held company in Manalapan, New Jersey, is the leading provider of multi-channel sample management solutions for pharmaceutical and biotech companies. Supported by more than 75 years of combined pharmaceutical leadership experience, RxS has been partnering with pharmaceutical and biotech companies since its founding in 2011 to provide regulatory compliance in order to lessen the administrative burden of the Prescription Drug Marketing Act. RxS offerings go beyond regulatory compliance, providing solutions to increase marketing and sample effectiveness. Driven by technology, RxS offers a suite of proprietary services and software solutions to ensure regulatory compliance and maximize analytics data. RxS’s commitment to innovative solutions extends beyond their service offerings and into the community through a unique partnership with Academy Learning Centers where students with disabilities are offered employment opportunities to help develop self-reliance and foster an improved sense of self.
# # #
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/e51f0c1c-bec0-4d23-b18f-776290ba6cf5
Attachments:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c05c5f83-92e6-432f-8d55-475c63de1855